RICHMOND, Va. (Nov. 20, 2009) — Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth.
According to Paul B. Fisher, M.Ph., Ph.D., professor and chair of the Department of Human and Molecular Genetics, director of the VCU Institute of Molecular Medicine in the VCU School of Medicine, and program leader of Cancer Molecular Genetics at the Massey Cancer Center, the team has shown that astrocyte elevated gene-1, AEG-1, a cancer promoting gene, is involved in both oncogenic transformation, which is the conversion of a normal cell to a cancer cell, and angiogenesis, which is the formation of new blood cells. Oncogenic transformation and angiogenesis are critical for tumor development, growth and progression to metastasis.
In the study published online the week of Nov. 16 in the Early Edition of the journal Proceedings of the National Academy of Sciences, researchers employing a series of molecular studies reported that the elevated expression of AEG-1 is involved with turning normal cells into cancer cells.
According to Fisher, when AEG-1 was expressed in normal immortal rat embryo fibroblast cells it converted these cells into transformed cells that induced rapidly growing aggressive cancers when injected into animals. AEG-1 expressing cells displayed enhanced expression of genes regulating blood vessel formation, thereby contributing to tumorigenicity. The team has further defined the pathways in target cells that are activated by AEG-1 and mediate its oncogenic and angiogenic inducing properties.
“Our goal is to understand the functions of a novel gene AEG-1 that plays an essential role in tumor progression, with potential to develop effective therapeutic approaches for multiple cancers through targeted inhibition of this novel molecule or its downstream regulated processes,” said Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center.
“We believe it will pave the way for ameliorating the sufferings of scores of cancer patients by uncovering new and effective avenues for treatment,” he said.
To expand the work on AEG-1, the VCU Department of Human and Molecular Genetics, Institute of Molecular Medicine and Massey Cancer Center recently received a National Cancer Institute grant totaling $1.6 million to study the AEG-1 gene in the context of malignant brain tumors such as glioblastoma multiforme, or GBM. According to Fisher, who is the primary investigator for the study, the work will extend the understanding of this gene and how it may serve as an oncogenic, or transforming gene.
“Cancer development and progression are multi-factor and multi-step processes that occur in a temporal manner. As mentioned above AEG-1 clearly has multiple roles in various steps of tumor progression, including tumor cell growth, insensitivity to growth-inhibitory signals, including chemotherapeutic agents, invasion, angiogenesis and metastasis,” explained Fisher.
“In addition, AEG-1 has been known to have oncogenic roles in various cancers including glioma (CNS tumor), neuroblastoma, liver cancer, breast cancer, prostate cancer, lung cancer, and esophageal squamous cell carcinoma. These important correlations make this gene an intriguing molecule to study with potential to serve as a direct target for cancer therapy,” he said.
The gene was discovered in 2002 in Fisher’s laboratory while he was at the Columbia University College of Physicians and Surgeons in New York.
Fisher worked with a team that included VCU School of Medicine researchers Zao-zhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, M.B.B.S., Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; Hyun Yong Jeon, M.S., research assistant with the VCU Department of Human and Molecular Genetics; Luni Emdad, M.D., Ph.D., with the Mount Sinai School of Medicine in New York; and Habib Boukerche, Ph.D., a senior scientist with the University Lyon 1 in France.
About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, public research university and the largest doctoral institution in Virginia with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 32,000 students in 205 certificate and degree programs in the arts, sciences and humanities. Sixty-five of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.
About the VCU Massey Cancer Center: The VCU Massey Cancer Center is one of 65 National Cancer Institute-designated institutions that leads and shapes America’s cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers more clinical trials than any other institution in Virginia, serving patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 1-877-4-MASSEY.
